Latest Commercial Growth News

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Decidr AI Industries Ltd (ASX: DAI) reported a doubling of its annualised revenue run rate to A$8.06 million as of March 2026, alongside the launch of its Decidr Agentic Graph platform and significant expansion of its partner ecosystem.

Metal Powder Works nearly doubled its powder revenue in Q1 2026 while maintaining strong margins, secured its first NATO defence contract under the UK Ministry of Defence’s Project TAMPA, and advanced its Next Gen powder production system on schedule.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

RPM Automotive has appointed Roy Norris as its new CEO, replacing Clive Finkelstein who served since September 2024. Norris brings extensive industry experience aimed at steering RPM's strategic growth.

Brisbane Broncos Limited celebrated a landmark 2025 with premiership victories in both the NRL and NRLW, driving a 36% jump in net profit to $7.77 million and underpinning strong commercial growth.

EBR Systems has reported a significant increase in commercial implantations of its WiSE System in Q1 2026, more than doubling case volumes from the previous quarter and projecting preliminary revenue between US$2.25 million and US$2.36 million.

TZ Limited (ASX:TZL) has secured $0.81 million through a private placement at a 22% premium to the last traded price, issuing 16.2 million shares with attaching options pending shareholder approval. The funds will support debt repayment, vendor payments, working capital, and growth initiatives in smart locking and data centre security.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.